View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Emisphere Technologies
26 November 2018

Emisphere Gives Update on Development

On 22-23 November, Novo Nordisk announced the completion and results of its Pioneer 9 and Pioneer 6 phase 3a trials, both conducted with an oral semaglutide, a once-daily oral formulation of the long-acting GLP-1.

Novo Nordisk announced the completion and results on Thursday, November 22 and Friday, November 23 regarding their Pioneer 9 and Pioneer 6 phase 3a trials, both conducted with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog. Both studies utilized Emisphere Technologies, Inc. (“Emisphere” or the “Company”) (OTCBB: EMIS) proprietary Eligen® SNAC Carrier Technology. These two clinical trials represent the completion of Novo Nordisk’s ten-study Pioneer phase 3a oral semaglutide clinical program.

A copy of the detailed Novo Nordisk’s study announcements on the Pioneer 9 and Pioneer 6 studies can be viewed at the following respective links:

https://www.novonordisk.com/bin/getPDF.2226662.pdf

https://www.novonordisk.com/bin/getPDF.2226789.pdf

Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
Originally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label, randomised, single-dose, parallel-group study of the pharmacokinetics of oral cyanocobalamin...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology